BIONIC EYE TRIAL RESULTS SHOW SUBSTANTIAL VISION IMPROVEMENTS OVER TWO AND A HALF YEARS Blind participants with retinitis pigmentosa able to locate doorways, avoid obstacles
SEGMENT
Filmed in Melbourne and Sydney | February 2025
Released on Retinitis Pigmentosa Awareness Month
INTERVIEWED
Professor James Fallon,
Chief Technology Officer Bionics Institute &
Head of the Medical Bionics Department, University of Melbourne
Associate Professor Penelope Allen,
Head of Bionic Eye Project & Principal Investigator,
Centre for Eye Research Australia (CERA) &
Vitreoretinal Surgeon,
Royal Victorian Eye and Ear Hospital
Dr Ash Attia
Chief Executive Officer & Managing Director
Bionic Vision Technologies
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, were published in Ophthalmology Science.
The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
Retinitis pigmentosa is an inherited retinal disease which affects about two million people worldwide and is one of the leading causes of vision loss in working-age people.
The bionic eye comprises an electrode array, designed by the Bionics Institute and the Centre for Eye Research Australia, that is surgically implanted behind the eye. The electrode receives signals from a video camera mounted on glasses, which stimulate the patient’s retina.
Credit: Retinitis pigmentosa fact sheet from Retina Australia
-
NSW Medical Device Commercialisation Training Program (MDCTP) Graduation 2019
Cicada Innovations with NSW Health this week hosted the graduation night for the 15 individuals that were part of the NSW Medical Device Commercialisation Training Program (MDCTP).
-
New horizons in unified oral health care
The Oral Health Association of Australia (OHAA) is the peak professional association representing Oral Health Practitioners (dental hygienists, dental therapists and oral health therapists) to support and promote the continued growth and development of oral health across Australia.
In October 2025, OHAA held its inaugural Congress as a new association entity to celebrate and advance the shared goals of the oral health workforce and community. This year’s Congress was held to foster learning, collaboration, and growth in the field of oral health.
-
Addressing Wound Management
The cost of chronic wounds in Australia is estimated to be $3 Billion per year, impacting 420,000 Australians. Not only is this a national economic concern, but more importantly, is the suffering the person may be going through.
Australian Health Journal met with Hayley Ryan, Board Director and Chair at Wounds Australia and Director at WoundRescue to hear her work in chronic wound management, palliative wounds and pressure injury prevention to comfort those living with a wound.
